Skip to content
‹ Back to IndustriesSciences

POLYGON HEADS TO WASHINGTON, D.C. FOR THE 2018 ARCHIVES RECORDS EXPO

The Annual Archives Records Expo is the place to be this month for professionals engaged in preservation work. It’s an excellent opportunity to learn the latest in best practices from the archives profession’s industry partners and thought leaders. Those just entering the field as well as leaders with decades of insights and experience to share…

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

By Promoted Content · · Promoted Content
Share
POLYGON HEADS TO WASHINGTON, D.C. FOR THE 2018 ARCHIVES RECORDS EXPO

Key takeaways

01

The Annual Archives Records Expo is the place to be this month for professionals engaged in preservation work.

02

It’s an excellent opportunity to learn the latest in best practices from the archives profession’s industry partners and thought leaders.

03

Those just entering the field as well as leaders with decades of insights and experience to share…

Free workspace

Turn your Sciences expertise into content.

Record interviews, organize footage, and write with AI on a free trial of the MarketScale platform for qualifying companies. No demo required, no credit card.

Try it Free

The Annual Archives Records Expo is the place to be this month for professionals engaged in preservation work. It’s an excellent opportunity to learn the latest in best practices from the archives profession’s industry partners and thought leaders. Those just entering the field as well as leaders with decades of insights and experience to share come together to network with colleagues and take back to their organization’s new ideas for improving their preservation work.

Coming up on August 12-18 at the Marriott Wardman Park in Washington, D.C., the Archives Records 2018 Expo is a joint event run by the Society of American Archivists, the Council of State Archivists, and the National Association of Government Archives and Records Administrators. Polygon Group could not be more pleased to exhibit at this premier annual event for archivists!

Event Highlights

This annual event will feature several useful workshops and expert speakers. Topics include managing architecture, design and construction records, how to archive scientific materials, and communications and media training for archivists. Attendees will also have the opportunity to learn more about teaching with primary sources, revising best practices on accessibility, building support for digital archives, and designing appropriate policies for the use and capture of government records.

Follow the conference Twitter hashtag (#saa18) and keep an ear out for session-specific hashtags (ex: #saa301).

Look for Polygon at the Expo!

Polygon is an exhibitor at this joint conference and looks forward to connecting with other professionals in the archiving world. Polygon uses a state-of-the-art desiccant air dry distribution system that thoroughly dries hard copy documents and multimedia damaged by water, fire, and mold. Our energy saving technology allows us to dry, clean and/or reproduce materials much more efficiently than other drying systems. Find us at booth 403.

The vacuum freeze-drying process is the most efficient and effective method for the drying of wet papers and other documents. Using this method, Polygon technicians can restore water-damaged materials quickly and effectively, reducing back processing time by 20 to 30 percent. Learn more about Polygon’s document restoration services ahead of the expo by visiting

polygongroup.com/en-US/services/document-recovery-solutions/.

We hope to see you throughout the expo. Be sure to stop by booth 403 to say hello!

Read more at polygongroup.com

Your experts belong here

Every story in MarketScale Sciences starts with a company putting its lab directors, applications scientists, and field specialists on the record. Buyers are already reading this topic. The only question is whose experts they find.

Lab and research buyers verify before they trial, and your scientists give them something credible to verify against.

Book DemoSee how it works15 minutes, straight to a calendar.

About the author

PC
Promoted Content
B2B Weekly

The week in Sciences, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Sciences: are you visible to AI?

Before they reach out, Sciences buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free Trial

You just read one Sciences expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your lab directors, applications scientists, and field specialists into the articles, video, and social content Sciences buyers are searching for. Start a free trial and see it with your own people. For qualifying companies, no credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What your free trial includes

Hands-on access to the MarketScale platform
Media requests to your crowd, remote recording, AI writing tools
No demo required. No credit card.
For qualifying companies. Company confirmation required.

More Sciences Insights

Antibody developability checks are moving into discovery instead of waiting for development

Antibody developability checks are moving into discovery instead of waiting for development

Maria Gonzalez-Pajuelo of FairJourney Bio says the order in antibody discovery is changing: developability has become a much more important consideration during discovery, rather than an issue left until later-stage development. The goal, she says, is that what comes out of discovery is something CMC can take forward easily.

  • 01Discovery-stage developability screens can rank many antibodies tested once or twice and may reduce surprises later in development, while development still focuses on several lots of a single antibody and answers different questions.

Oct 1, 2026

Caraballo expects AI across all five tracks at ISPE’s 2026 Annual Meeting

Caraballo expects AI across all five tracks at ISPE’s 2026 Annual Meeting

ISPE’s 2026 Annual Meeting and Expo in Washington, DC organizes its program around five tracks running from discovery to governance, with international program committee chair Connie Langer of Pfizer Global Supply and executive chair Jose Caraballo of JCO Global Advisory LLC describing how the tracks connect—and why AI is treated as a cross-cutting topic rather than a standalone track. Deloitte’s December 2025 survey of 280 executives frames the mood the program is built for.

  • 01ISPE’s 2026 Annual Meeting has no dedicated AI track; executive chair Jose Caraballo expects AI presentations across all five tracks, from discovery to governance.
  • 02Deloitte’s December 2025 survey of 280 biopharma and medtech C-suite executives found more than 75% confident in their own outlook but only 41% optimistic about the global economy, a mood the story says the ISPE chairs are programming for.
  • 03A staffing firm reports life sciences job openings falling even as digital fluency becomes a required skill, so the upskilling burden lands on the people already employed, which is where the mandatory, university-partnered AI training Connie Langer describes at her company sits.

Sep 30, 2026

Crown Bioscience's San Diego site fits the tumor model to the therapy, not the reverse

Crown Bioscience's San Diego site fits the tumor model to the therapy, not the reverse

Crown Bioscience's San Diego site designs preclinical tumor models to match specific therapies and delivery routes, rather than forcing treatments into standard study designs. It combines custom surgical procedures, cell line-derived xenografts, patient-derived xenografts (including post-treatment models), and biomarker capabilities to generate translational data that can help sponsors decide whether to advance a program.

  • 01Orthotopic brain tumor implantation using tagged models lets researchers track tumor growth in the original organ, aligning the model and delivery route with how therapies are intended to be tested.
  • 02Patient-derived xenografts developed from tumors after prior treatment may better reflect progressed disease, helping teams study therapies aimed at patients whose cancer has advanced after earlier treatment.
  • 03Combining biomarker analysis of preclinical model samples with clinical sample testing at one site could make it easier to connect what is measured in animals with what is later measured in patients.

Sep 30, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Expert

PC
Promoted Content

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Sciences and beyond.

Book a Demo

Or call us. No forms required. We pick up. 214-945-2512